Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 16;10:952726. doi: 10.3389/fbioe.2022.952726

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Ong, Chia, Wong, Zhang, Chua, Loo, Chua, Chua, Tan, Hentze, Tan, DasGupta and Toh.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

In vivo-in vitro comparative study to evaluate the efficacy of 5 standard-of-care (SOC) chemotherapies for 3 CRC patients. (A) Experimental design. The 5 SOC chemotherapies tested were 5-Fluorouracil (5-FU), Oxaliplatin (OXA), irinotecan (IRI), 5-Fluorouracil + Oxaliplatin (5-FU + OXA or 5-FU/OXA), and 5-Fluorouracil + irinotecan (5-FU/IRI). Figure created with BioRender.com. (B) Calcein-AM fluorescent images overlaid with transmission images showing viability of CRC 1414 tumour spheroids in IMITA devices after 24 h of treatment with 5 SOC chemotherapies at selected concentrations. Magnification = ×10. Scale bar = 250 µm.